Buprenorphine Sublingual C-Iii has 8 known drug interactions based on U.S. FDA drug labeling data. 2 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Alcohol, Nitrazepam, Atazanavir. Patients taking Buprenorphine Sublingual C-Iii should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 8
- Major
- 2
- Moderate
- 4
Major (2)
- Buprenorphine Sublingual C-Iii + Alcohol— Additive CNS depressant effects increase risk of respiratory depression, profound sedation, coma, and death.
- Buprenorphine Sublingual C-Iii + Nitrazepam— Additive CNS depressant effects increase risk of respiratory depression, profound sedation, coma, and death.
Moderate (4)
- Buprenorphine Sublingual C-Iii + Atazanavir— Other PIs with CYP3A4 inhibitory activity (atazanavir and atazanavir/ritonavir) resulted in elevated levels of buprenorp…
- Buprenorphine Sublingual C-Iii + Erythromycin— CYP3A4 inhibitor increases buprenorphine plasma concentration, resulting in increased or prolonged opioid effects.
- Buprenorphine Sublingual C-Iii + Ketoconazole— CYP3A4 inhibitor increases buprenorphine plasma concentration, resulting in increased or prolonged opioid effects.
- Buprenorphine Sublingual C-Iii + Ritonavir— CYP3A4 inhibitor increases buprenorphine plasma concentration, resulting in increased or prolonged opioid effects.